Nanoparticle-Lipid Composite Carriers for Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipid-based nanocarriers for drug delivery face challenges such as instability, low capacity for lipophilic drugs, and lack of controlled-release mechanisms, limiting their therapeutic and diagnostic efficacy in cancer treatment and imaging.
Innovation Solution
Development of nanoparticle-lipid composite carriers with a magnetic, plasmonic, or semiconducting core and a functionalized nanoparticle shell, enabling controlled drug loading and release under external RF fields, enhancing diagnostic contrast and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lipid-based nanocarriers are used for drug delivery, then biocompatibility and biodegradability are improved, but stability and controlled-release capability deteriorate
Solution Approach 1:
The patent combines magnetic nanoparticles with lipid-based nanocarriers to create a composite structure that integrates the biocompatibility of lipids with the stability and functional properties of magnetic nanoparticles, resolving the contradiction between biocompatibility and stability
2Reliability
If lipid-based nanocarriers are used for drug delivery, then biodegradability is improved, but capacity to load lipophilic drugs deteriorates
Solution Approach 1:
The patent embeds magnetic nanoparticles within the lipid nanocarrier structure, creating a nested configuration where the core provides drug loading capacity and the shell provides biodegradability, allowing simultaneous achievement of both properties
3Device complexity
If lipid-based nanocarriers are used for drug delivery, then simplicity of structure is improved, but controlled-release mechanism deteriorates
Solution Approach 1:
The patent introduces dynamic control of drug release through external magnetic field application, allowing the release mechanism to transition from passive to actively controlled, enhancing versatility while maintaining relatively simple carrier structure
4Measurement precision
If magnetic nanoparticles are used as T2 MRI contrast agents, then diagnostic imaging capability is improved, but therapeutic function deteriorates
Solution Approach 1:
The patent creates a multifunctional platform where magnetic nanoparticles simultaneously serve as MRI contrast agents and therapeutic carriers, enabling both diagnostic imaging and drug delivery functions within a single system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle-lipid composite carriers demonstrate high MR contrast and controlled drug release, achieving up to 75% cell death in cancer cells, making them a versatile theranostic platform for cancer diagnosis and treatment.
Implementation Method 1
Magnetic nanostructures (MNS) have received significant attention due to their ability to enhance localized contrast in magnetic resonance imaging (MRI) and heat under external radio frequency (RF) field
Implementation Method 2
Magnetic nanostructures (MNS) have received significant attention due to their ability to enhance localized contrast in magnetic resonance imaging (MRI)
Implementation Method 3
the hydrophobic core allows drug loading in a controlled manner
Data Source
AI summary
Provided herein are nanoparticle-lipid composite carriers as theranostic agents, particularly for diagnosis and/or treatment of cancers and related diseases and conditions. In particular embodiments, the carrier composites comprise a lipid core and an outer shell of functionalized nanoparticles (fNPs).